ClinicalTrials.gg
CompletedNCT05677425Updated Apr 11, 2025Results posted

Temperature Profiles During Laser Activation in Ureteroscopic Lithotripsy

An interventional study of Temperature measurement in Ureteral Stone, sponsored by Haukeland University Hospital. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Haukeland University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary aim of this study is to investigate the temperature profiles in the renal pelvis during ureteroscopic Thulium Fiber Laser activation using different settings. To this end, comparison of peak temperatures during laser activation for different settings is the main aim. Secondary aim is trying to define the duration of safe laser activation until the threshold for heat induced cell injury (43oC) is reach.

Patients ≥ 18 years with a ureteral stone (with or without a concomitant renal stone) and an indwelling nephrostomy tube scheduled for ureteroscopic lithotripsy at the day surgery unit at Haukeland University Hospital, are eligible to enrolment in the study.

Temperature measurements during ureteroscopic laser stone disintegration will be performed. Follow-up is standardised with clinical consultation and low dose CT 3 months post endoscopically.

Read the detailed description

BACKGROUND: The Holmium:Yttrium-Aluminium-Garnet (Ho:YAG) has been considered the gold-standard laser for ureteroscopy (URS) because of its versatility, with the ability to break all kinds of stones in the urinary tract as well as tumor- and soft tissue ablation. Development of higher power laser technology has allowed the limits of what can be achieved with URS to be set even higher. In comparison to stone fragmentation, techniques such as dusting and pop-corning often implement higher power settings (>20 Watts), and the efficacy associated with different strategies has been the focus of many studies. Intraoperative safety of URS has gained increased attention, particularly with regard to raised temperature levels. Recently, a new Thulium Fiber Laser (TFL) has been introduced. With the advent of the TFL, discussion surrounding high temperatures during lithotripsy and resultant thermal damage have been fueled further. Defining safe margins for laser settings is especially important for the TFL as no consensus exists for what is acceptable during URS. To date, there are no clinical studies investigating intrarenal temperatures during URS laser treatment. Studying temperature profiles during URS laser activation in patients is therefore of critical importance and highly clinically relevant to define the safety of different laser settings and power.

AIMS OF THE STUDY: The primary aim of this study is to investigate the temperature profiles in the renal pelvis during TFL laser activation using different settings. To this end, comparison of peak temperatures during laser activation for different settings is the main aim. Secondary aim is trying to define the duration of safe laser activation until the threshold for heat induced cell injury (43oC) is reach.

THE URETEROSCOPIC PROCEDURE AND TEMPERATURE MEASUREMENTS: The URS procedure is performed in general anaesthesia and all patients will have prophylactic antibiotics prior to surgery start, either according to urine culture or current local regime.

The procedure starts with a cystoscopy followed by semirigid URS when considered appropriate. Balloon dilatation is performed on demand. When reaching the stone, this is flushed back into the renal pelvis for disintegration there if possible. In cases where the stone cannot be flushed back into the renal pelvis, the stone is disintegrated in situ before the endoscope is advanced up to the renal pelvis for temperature measurements. Before laser disintegration, the semirigid ureteroscope is changed for a flexible ureteroscope that is advanced to the renal pelvis directly or over a guide wire that must be removed as soon as the endoscope is in place. An access sheath cannot be used during this study. Room-tempered (23oC), gravitational irrigation fluid at 60 cm height is used throughout the procedure. Manual pumping should be avoided and should in any case not be performed during the temperature measurements.

Under endoscopic vision, a sterilized thermocouple sensor (K-type, same as in the pre-clinical study) is introduced through the nephrostomy tube so that the tip can identified through the side-holes of the nephrostomy tube. The stone is moved to the central renal pelvis for laser disintegration, and a 150μm laser fiber is introduced into the renal pelvis through the working channel of the flexible ureteroscope. At this point the nephrostomy tube is clamped to achieve filling of the renal pelvis and to mimic a normal procedure.

Laser disintegration of the stone is started using the lowest laser setting of 5 Watts continuously for 120 seconds followed by 60 seconds of idling laser. Temperature measurements are maintained continuously during these 180 seconds, with two measurements per second. When the temperature in the renal pelvis has reached base temperature after one series of measurements, the procedure is repeated for the next laser setting. In total, URS lithotripsy are performed for three different settings. If 43oC is reach during laser activation for any of the laser settings, the laser will be stopped immediately and further laser activation with that specific settings will be aborted. Laser activation with subsequent settings will be ready when base temperature is reached.

If stone treatment is not completed at the end of the three series of laser activation and temperature measurements, further stone disintegration will be performed before finishing the URS procedure.

A double J-stent is placed at the end if deemed necessary by the surgeon. The nephrostomy tube is removed when considered appropriate. If a double J-stent is placed after the procedure, this is removed according to standard routine after 1-2 weeks in the outpatient clinic.

FOLLOW-UP: Follow-up with CT is performed at 3 months post endoscopically for all patients to assess stone free status and exclude a ureteral stricture in addition to a clinical consultation.

LASER SETTINGS: The following laser settings will be used in the study:

5 watts of power: 0.5 Joules (J) / 10 Herz (Hz), short pulse 10 watts of power: 0.5 J / 20 Hz, short pulse 20 watts of power: 0.5 J / 40 Hz, short pulse 30 watts of power: 1 J / 30 Hz, short pulse

ETHICAL CONSIDERATION AND APPROVALS: Participation in the study is voluntarily, and the patient can choose to withdraw at any point during the study process. Inclusion in the study will only be done after the consent form is signed.

The study is approved by The National Committees for Research Ethics in Norway (REK-550816). Application for approval by The Data Protection Authorities at Haukeland University Hospital has been sent.

02

Conditions studied

  • Ureteral Stone

Browse trials for

03

In context

Ureterolithiasis

84 studies on the registry are indexed under Ureterolithiasis; 19 are open to participants now.

This study's enrollment of 10 is below the median of 101 across 66 interventional studies indexed under Ureterolithiasis.

Browse Ureterolithiasis studies →

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years with a ureteral stone (with or without a concomitant renal stone) and an indwelling nephrostomy tube scheduled for URS lithotripsy at the Day Surgery unit at Haukeland University Hospital

Exclusion criteria

Exclusion Criteria:

  • Urinary diversion
  • Active infection
  • Untreated cancer in the upper urinary tract
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Temperature measurement group

    Temperature measurement in the renal pelvis during ureteroscopic laser stone disintegration. Temperature measurement will be performed using different laser power settings.

    Other: Temperature measurement

Interventions

  • OtherTemperature measurement

    Temperature measurement in the renal pelvis during ureteroscopic laser activation.

06

What researchers measure

Primary outcomes

  1. Temperature Profiles

    Temperatures during ureteroscopic laser activation using different laser power settings.

    Time frame: During surgery

07

Results

Posted Mar 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneTemperature Measurement Group
Started10
Completed10
Not completed0

Outcome measures

PrimaryTemperature Profiles

Temperatures during ureteroscopic laser activation using different laser power settings.

Time frame:
During surgery
Reported as:
Mean · Degrees Celcius
Temperature Profiles
Degrees CelciusTemperature Measurement Group
Baseline temperature32.5 (31.7 to 33.2)
Tmax 5 W35.3 (34.6 to 36.9)
Tmax 10 W37.9 (36.4 to 39.4)
Tmax 20 W40.0 (39.0 to 41.1)

Adverse events

Collected over From study start until 3 months follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temperature Measurement Group0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventTemperature Measurement Group
Clavien-Dindo 1 and 2Renal and urinary disorders3/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temperature Measurement Group
Mean57 (42 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Temperature Measurement Group
Female8
Male2
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Temperature Measurement Group
Stone size, mm
Stone size, mm(mm)Temperature Measurement Group
Mean9 (5 to 16)
08

Study locations

1 site
  • Haukeland University Hospital
    Bergen, Vestland 5021, Norway
09

References and documents

Publications

  • AEsoy MS, Juliebo-Jones P, Beisland C, Ulvik O. Temperature Measurements During Flexible Ureteroscopic Laser Lithotripsy: A Prospective Clinical Trial. J Endourol. 2024 Apr;38(4):308-315. doi: 10.1089/end.2023.0660. Epub 2024 Feb 28. PubMed 38185920 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jun 2023, 5 months.

Results were first posted in Mar 2025, 1 year 8 months after primary completion.

Of 36 non-industry interventional studies with no phase under Ureterolithiasis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 5 months is below that.

Counting every sponsor, half of 38 studies reached it within 20 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 10, 2023
StartActual
Jan 23, 2023
Primary completionActual
Jun 30, 2023
CompletionActual
Jul 1, 2023
Results first posted
Mar 24, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05677425
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jan 23, 2023
Primary completion
Jun 30, 2023
Completion
Jul 1, 2023
Results posted
Mar 24, 2025
Last update
Apr 11, 2025

Study contacts

Øyvind Ulvik, Assoc Prof
principal investigator · Haukeland University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion